Relay Medical's Glow LifeTech Investment Files Natural Health Product with Health Canada, Following Successful COVID-19 Phase II Clinical Trial and North American Exclusive Rights

Toronto, Ontario--(Newsfile Corp. - April 27, 2021) - Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) ("Relay" or the "Company"), a shareholder of Glow LifeTech Corp. (CSE: GLOW) (FSE: 9DO) ("Glow"), is pleased to provide an update on recently disseminated news by Glow LifeTech Corp.

Cannot view this image? Visit:
Glow LifeTech's natural health product - ArtemiC™

To view an enhanced version of this graphic, please visit:

On April 27, 2021, Glow reported on submitting an application to Health Canada to obtain produce licenses for its Natural Health Product (NHP), ArtemiC™, which reported successful results from a COVID-19 Phase II clinical trial.1

Glow is a biotech company focused on producing next-generation, science-backed natural products. ArtemiC™ was submitted to Health Canada's Natural and Non-prescription Health Products Directorate (NNHPD) on Mar 11, 2021. The application, which is currently under review by Health Canada, included ArtemiC™, which Glow receive exclusive rights to in early February.2

"Canada has the potential to set the world stage for COVID-19 Natural Health Products. With Health Canada approval and favorable clinical results, ArtemiC™ could become an evidence backed all-natural solution to aid patient recovery," stated Yoav Raiter, CEO, Relay Medical Corp. "Glow has exclusive rights to market, sell, and distribute ArtemiC™ in Canada, the United States, Mexico, and all Caribbean countries as a food supplement (nutraceutical, dietary supplement, and natural health product)."

For the full and complete update from Glow, please refer to their news release3:

The Company is not making any express or implied claims that it has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

About Glow LifeTech Corp.
Glow LifeTech is a Canadian-based biotechnology company focused on producing nutraceutical and cannabinoid-based products with enhanced bioavailability, absorption, and effectiveness. Glow has rights to the groundbreaking, plant-based MyCell Technology® delivery system, which transforms poorly absorbed natural compounds into enhanced water-compatible concentrates that unlock the full healing potential of valuable ingredients.


About Relay Medical Corp.

Relay Medical is a technology innovator headquartered in Toronto, Ontario with a team of experts focused on the development of novel technologies in the diagnostics and AI data science and IoT security sectors.


For Media Inquiries, please contact: Destine Lee | 647-872-9982

SUBSCRIBE: For more information on Relay or to subscribe to the Company's mail list visit:

W. Clark Kent
Relay Medical Corp.
Office. 647-872-9982 ext. 3
TF. 1-844-247-6633 ext. 3

Bernhard Langer
EU Investor Relations
Office. +49 (0) 177 774 2314

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. There are no assurances that the commercialization plans for the technology described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at

1 ArtemiC™ Full Trial Results (Dec 15, 2020):

2 February 16, 2021


To view the source version of this press release, please visit